Greenwich LifeSciences Launches FLAMINGO-01 in Poland
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), known for its commitment to advancing healthcare through clinical research, has made a significant step by activating its Phase III clinical trial, FLAMINGO-01, in Poland. This trial focuses on GLSI-100, an innovative immunotherapy aimed at preventing breast cancer recurrences.
The Need for Effective Breast Cancer Solutions
The urgency for new treatments in oncology becomes clearer when examining the alarming cancer statistics. Breast cancer accounted for 24,599 new diagnoses in Poland, reflecting its status as the most prevalent cancer among women, making up approximately 25% of all female cancer cases. Tragically, the disease is not just common; it remains the second leading cause of cancer death among women, with 8,723 deaths reported last year. These statistics highlight the critical need for effective therapies in oncology.
Collaboration with Leading Experts
Greenwich LifeSciences proudly collaborates with Dr. Piotr Wysocki, a renowned oncologist who leads Poland's expansive breast cancer research network. Under his guidance, 9 to 11 clinical sites have been approved to participate in the FLAMINGO-01 trial, indicating a strong commitment to research and patient care.
These clinical sites received authorization from Polish regulatory authorities, paving the way for site initiation visits and enabling the treatment of the first patient as the trial commenced. Dr. Wysocki serves as the national principal investigator for Poland, where his expertise and dedication to breast cancer research will be invaluable.
Positive Outcomes from a Comprehensive Approach
CEO Snehal Patel expressed optimism regarding the clinical trial, stating, "Poland has a reputation for high-quality treatment centers with robust patient enrollment capabilities. Working alongside Dr. Wysocki, who has demonstrated exceptional standards in patient care and research, we expect to achieve significant milestones in the FLAMINGO-01 trial. We may also enhance our study's outreach by including participants from Ukraine who have recently relocated to Poland due to the ongoing crisis."
The dedicated clinical sites include several respected institutions across Poland, including:
- Konin: KOMED Oncology Center
- Kraków: Samodzielny Publiczny Zak?ad Opieki Zdrowotnej Szpital Uniwersytecki, Szpital Specjalistyczny im. Ludwika Rydygiera
- Opole: Samodzielny Publiczny Zak?ad Opieki Zdrowotnej Opolskie Centrum Onkologii
- Pozna?: Uniwersytecki Szpital Kliniczny
- Rzeszów: Centrum Medyczne MrukMed
- Slupsk: Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka
- Warszawa: Wojskowy Instytut Medyczny, Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie
Understanding FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is rigorously structured to evaluate the safety and effectiveness of GLSI-100, a groundbreaking treatment specifically designed for HER2 positive breast cancer patients who exhibit residual disease post-surgery. Participants in the trial have completed both neoadjuvant and postoperative adjuvant treatment based on trastuzumab.
The Baylor College of Medicine leads this high-level clinical trial, which is currently expanding beyond the United States and aims to initiate up to 150 clinical sites worldwide. The double-blinded study randomly allocates approximately 500 patients whose histocompatibility leukocyte antigen type is HLA-A*02 to receive either GLSI-100 or a placebo. An additional group of up to 250 patients with other HLA types will also have the opportunity to receive this investigational treatment.
The Importance of HER2 and Breast Cancer
Breast cancer continues to challenge healthcare providers, with one in eight U.S. women facing a diagnosis of invasive breast cancer in their lifetime. HER2 positivity signifies the presence of a specific receptor that plays a critical role in many breast cancer cases, seen in nearly 75% of patients. Understanding and targeting HER2 is essential in developing effective immunotherapies, like GLSI-100, to improve patient outcomes.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is dedicated to revolutionizing cancer treatment through innovative approaches and cutting-edge research. The company focuses on the development of GP2, a targeted immunotherapy designed to help patients avoid recurrent breast cancer after surgery. With their commitment to rigorous clinical research, Greenwich LifeSciences is positioning itself at the forefront of oncology care.
For more information about their latest advances and initiatives, please visit the company's website or reach out to their media relations team.
Frequently Asked Questions
What is the FLAMINGO-01 trial?
The FLAMINGO-01 trial is a Phase III clinical study that explores the safety and effectiveness of GLSI-100 in patients with HER2 positive breast cancer.
Why is the trial being conducted in Poland?
Poland has renowned treatment centers and a strong patient enrollment capability, making it an ideal location for the trial.
Who is leading the research in Poland?
Dr. Piotr Wysocki, a prominent oncologist and researcher, is leading the study in Poland.
How does GLSI-100 work?
GLSI-100 is an immunotherapy designed to stimulate the patient's immune system to prevent breast cancer recurrences.
What are the expected outcomes of the trial?
The trial aims to demonstrate that GLSI-100 significantly improves cancer-free survival rates in participating patients.
